DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for oculocutaneous albinism type 2 — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOculocutaneous albinism type 2 maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oculocutaneous albinism type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
melanocortin 1 receptor (MC1R) — MC1R is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7F4H · 2.7 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
No drug treatment for oculocutaneous albinism type 2 is described in any of these abstracts. A 2023 review states plainly that there is no specific treatment for albinism; only palliative vision correction and sun-protection advice are available. A 2025 review mentions that emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies, but gives no drug name, no human data, and no efficacy results.
Genetic studies from 2015 and 2018 identify mutations in the OCA2 gene in Chinese families. In 2015, one patient was heterozygous for c.593C>T and c.1426A>G mutations in OCA2. In 2018, one proband had compound heterozygous mutations c.2359G>A and c.587T>C in OCA2. Both studies report that heterozygous family members carrying certain OCA2 mutations had blond or brown hair and pale skin at birth, with skin pigment accumulating over time and with sun exposure, but no ocular disorders. The 2018 study found that in one of six families, the clinical phenotype suggested OCA but genetic diagnosis was ocular albinism type 1 (OA1) instead.
The 2024 review lists 21 genes now associated with albinism, including 7 OCA-related genes (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA, and DCT). It states that the purpose of reviewing molecular genetics is to provide new ideas for prenatal or early diagnosis, not treatment. No abstract reports any clinical trial, any drug repurposing attempt, or any intervention that altered the course of the disease.
What is missing: any clinical trial testing a drug for OCA2, any repurposed compound with human data, any evidence that a pharmaceutical can increase melanin production or improve vision in these patients, and any stratified patient population in which such a trial could be conducted.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PLoS ONE · 2015 · 18 citations · open access
Mutational Analysis of the TYR and OCA2 Genes in Four Chinese Families with Oculocutaneous Albinism
AbstractBACKGROUND: Oculocutaneous albinism (OCA) is an autosomal recessive disorder. The most common type OCA1 and OCA2 are caused by homozygous or compound heterozygous mutations in the tyrosinase gene (TYR) and OCA2 gene, respectively. OBJECTIVE: The purpose of this study was to evaluate the molecular basis of oculocutaneous albinism in four Chinese families. PATIENTS AND METHODS: Four non-consanguineous OCA families were included in the study. The TYR and OCA2 genes of all individuals were amplified by polymerase chain reaction (PCR), sequenced and compared with a reference database. RESULTS: Four patients with a diagnosis of oculocutaneous albinism, presented with milky skin, white or light brown hair and nystagmus. Genetic analyses demonstrated that patient A was compound heterozygous for c.1037-7T.A, c.1037-10_11delTT and c.1114delG mutations in the TYR gene; patient B was heterozygous for c.593C>T and c.1426A>G mutations in the OCA2 gene, patients C and D were compound heterozygous mutations in the TYR gene (c.549_550delGT and c.896G>A, c.832C>T and c.985T>C, respectively). The heterozygous c.549_550delGT and c.1114delG alleles in the TYR gene were two novel mutations. Interestingly, heterozygous members in these pedigrees who carried c.1114delG mutations in the TYR gene or c.1426A>G mutations in the OCA2 gene presented with blond or brown hair and pale skin, but no ocular disorders when they were born; the skin of these patients accumulated pigment over time and with sun exposure. CONCLUSION: This study expands the mutation spectrum of oculocutaneous albinism. It is the first time, to the best of our knowledge, to report that c.549_550delGT and c.1114delG mutations in the TYR gene were associated with OCA. The two mutations (c.1114delG in the TYR gene and c.1426A>G in the OCA2 gene) may be responsible for partial clinical manifestations of OCA.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
ALBINISM DISEASE - CLASSIFICATION, DIAGNOSIS, SYMPTOMS AND TREATMENT MEASURES
AbstractAlbinism is a group of hereditary pathologies characterized by a violation or complete absence of skin, hair, eye pigmentation. The main symptoms of the disease are very pale skin and hair, blue or red eyes, and in some cases, vision impairment. The diagnosis of albinism is made based on the current condition of the patient, as well as genetic tests. To date, there is no specific treatment for albinism, palliative therapy (correction of vision) is used, and there are a number of recommendations for patients to behave in the sun, protect the skin and reduce the likelihood of complications
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
ALBINISM- A CONGENITAL DISORDER
AbstractABSTRACT Background: Albinism encompasses a group of inherited disorders characterized by reduced or absent melanin biosynthesis, affecting approximately 1 in 20,000 individuals worldwide with significant variability across geographical regions. These conditions present substantial clinical challenges and impact quality of life. Objective: This review aims to synthesize current understanding of albinism's genetic mechanisms, clinical manifestations, diagnostic approaches, available treatments, and emerging therapeutic strategies to provide a comprehensive framework for clinicians and researchers. Methods: A systematic literature search was conducted using PubMed, EMBASE, and Web of Science databases for articles published between 2000-2024, using keywords including "albinism," "oculocutaneous albinism," "ocular albinism," "melanin biosynthesis," "tyrosinase," and "albinism treatment." Studies were selected based on relevance, methodological rigor, and contribution to understanding albinism pathophysiology or treatment. Results: Recent advances have expanded understanding of albinism's genetic basis, with 22 genes now identified across various forms. Comprehensive phenotypic characterization has refined diagnostic approaches, while emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies. Conclusion: Albinism represents a paradigm for understanding melanin biology and neurodevelopmental visual pathways. While current management remains supportive, emerging molecular-based therapies may offer disease-modifying potential. Multidisciplinary approaches and increased awareness are essential to address both medical and psychosocial aspects of these conditions.
Journal of Contemporary Medical Practice · 2024 · 0 citations · open access
New Progress in Molecular Genetics Research of Albinism
AbstractAlbinism is a clinical and genetic heterogeneity disease associated with reduced melanin biosynthesis, characterized by visual system defects, manifested as poor vision, accompanied by varying degrees of pigment deficiency. The pigment deficiency can affect the eyes, skin, and hair in Oculocutaneous Albinism (OCA) or Oculocutaneous Albinosis (OA) that only affects the eyes. Currently, 21 genes related to albinism have been identified, including 7 OCA related genes (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA, and DCT), 1 OA related gene (GPR143), 1 FHONDA (SLC38A8), 1 CHS related gene (LYST), and 11 PHS related genes (HPS1, AP3B1, HPS3, HPS4, HPS5, HPS6, DTNBP1, BLOC1S3, BLOC1S6, AP3D1, and BLOC1S5). This article reviews the progress of molecular genetics research on albinism, with the aim of providing new ideas for prenatal or early diagnosis of albinism patients.
Pathogenic gene screening and phenotypic analysis of six albinism families
AbstractObjective
To analyze the pathogenic gene types and phenotypic characteristics of 6 albinism families.
Methods
A retrospective series of case studies. Six probands of albinism and 20 family members were recruited for this study, 5 probands with clinical manifestations of oculocutaneous albinism (OCA) and 1 proband of ocular albinism (OA). Genomic DNA was extracted from peripheral venous blood which was collected from 6 probands and 20 family members. Genetic variations were screened by whole-exome sequencing or Sanger sequencing and then analyzed the relationship between genotypes and phenotypes.
Results
Genetic sequencing identified 6 potential pathogenic variants in 4 probands, including 2 compound heterozygous mutations in the 2 genes [TYR (c.1037-7T> A, c.925_c.926insC), OCA2 (c.2359G> A, c.587T> C)] associated with OCA1 and OCA2, and 2 hemizygous mutations in the GPR143[GPR143 (c.11C> G), GPR143 (c.333G> A)] associated with OA1, respectively. In which, 5 were novel mutations and confirmed by Sanger sequencing. One case was accorded with OCA in clinical phenotype, but genetic diagnosis was OA1, the others were agreement between clinical diagnosis and genetic diagnosis.
Conclusion
There are 4 families with mutations in 6 families, representative of 3 type of albinism (OCA1, OCA2, OA1).
Key words:
Albinism, oculocutaneous/genetics; GPR143 gene; Heterozygote; Mutation
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
